The Ukrainian Pharmaceutical Market: Challenges and Solutions. The view of the leading expert of the European Union - Thomas Alonderis

       The global pharmaceutical market is a complex, multilevel, multifunctional entity with consistently high growth rates of production, sales and, accordingly, profitability. These reasons are related to the specificity of a medicinal product (LP) as a commodity that is  in demand, regardless of economic and political factors. The three pharmaceutical regions of the planet (the United States, Europe and Japan) account for about 80% of the total LP market. Despite the significant development of China, India, Brazil and Turkey, the US pharmaceutical market remains the largest in the world with annual growth rates.

The implementation structure of individual pharmacotherapeutic groups of medicines is mainly driven by national and regional characteristics, although there are general trends.

The main developments of new drugs are underway in the most significant therapeutic areas (oncology, cardiology, neurology and psychiatry, gastroenterology, diabetes, etc.), biopharmaceutical companies are gradually beginning to displace traditional manufacturers from such niches as the fight against overweight and asthma, asthma , cardiovascular disease and atherosclerosis, relief of sudden and chronic pain.

Based on the trends of political and economic situation in Ukraine, taking into account the prospects of the world pharmaceutical market, the main directions and priorities of the development of the national pharmaceutical market are:

-         - introduction of an effective mechanism for exercising state control over the production, sale and advertising of pharmaceutical products, as well as the quality of pharmaceutical products in the process of their production and import into the territory of Ukraine;

-         enhancing the competitiveness of pharmaceutical products and pursuing sound pharmaceutical policies;

-         creation of a quality management system for the whole cycle of drug trafficking by introducing good practice requirements;

-         improvement of the system of state registration, in particular through adaptation to international norms, first of all European countries;

-         introduction of multichannel financing of pharmaceutical science at the expense of budgetary and extra-budgetary funds, ensuring their rational use for the first priority financing of competitive scientific developments of fundamental and applied character;

               - implementation of a set of measures for substantiation and provision of information resources of the pharmaceutical market.

These issues are addressed by the Director of the Department of the Ministry of Health of Lithuania, adviser to the Committee on the Development of Pharmaceutical and Medical Technologies of the Association of Doctors of the Carpathian Region - TOMAS ALLONDERIS in his work "Choice of medicines and planning", to give an example of a farm. of the Lithuanian market to interpret the schemes of selling medicines in Ukraine.

Підписка на новини